News & Updates

Patients with obesity-related heart failure with preserved ejection fraction (HFpEF) treated with semaglutide are more likely to show an improvement in NYHA functional class at 52 weeks than those who received placebo, according to a study.

In the treatment of patients with type 2 diabetes (T2D) and obesity, metabolic/bariatric surgery appears to produce sustained weight loss over 12 years, translating to better physical function, general health, and vitality, as well as reduced pain, according to long-term data from the ARMMS-T2D Study.

New research has shown that a low-fat vegan diet rich in vegetables, fruits, whole grains, and legumes can improve insulin sensitivity in adult patients with type 1 diabetes (T1D), thus reducing their daily insulin requirements. The finding may fuel the momentum for dietary shifts in this population.

Poor glycaemic control appears to contribute to coronary stent failure driven by in-stent restenosis in patients with type 2 diabetes (T2D), suggests a study.

Semaglutide reduces the risk of major kidney disease-related events and death from cardiovascular causes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), as shown in the FLOW* study presented at ERA 2024.